ACRS Stock Summary and Trading Ideas (Aclaris Therapeutics | NASDAQ:ACRS)

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Aclaris Therapeutics trades on the NASDAQ stock market under the symbol ACRS.

As of April 1, 2026, ACRS stock price climbed to $4.14 with 1,341,814 million shares trading.

ACRS has a beta of 0.85, meaning it tends to be less sensitive to market movements. ACRS has a correlation of 0.03 to the broad based SPY ETF.

ACRS has a market cap of $448.28 million. This is considered a Small Cap stock.

Last quarter Aclaris Therapeutics reported $1 million in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-719,672 and missed earnings estimates by -$.02.

In the last 3 years, ACRS traded as high as $11.12 and as low as $.59.

The top ETF exchange traded funds that ACRS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

ACRS has outperformed the market in the last year with a price return of +170.6% while the SPY ETF gained +18.5%. ACRS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +37.5% and +6.7%, respectively, while the SPY returned -3.6% and -2.1%, respectively.

ACRS support price is $3.55 and resistance is $3.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRS shares will trade within this expected range on the day.